drugset / Trial / NCT04602754
Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Berlim 25/20 association in the treatment of type 2 diabetes mellitus and dyslipidemia.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2026-05
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Berlim 25/20 association | Unknown | — | Oral |
| Comparator | Empagliflozin | Small molecule | 25 mg | Oral |
| Comparator | Rosuvastatin | Small molecule | 20 mg | Oral |